The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partnership with HempStreet

4 May 2022 07:00

RNS Number : 2486K
MGC Pharmaceuticals Limited
04 May 2022
 

 

MGC Pharmaceuticals Ltd.

HempStreet announces partnership with MGC Pharma to revolutionise Global Phytomedicine Sector

4 May 2022

ASX, LSE: MXC

 

The Indian medicinal cannabis solution pioneer and the European biopharma company are combining their R&D and distribution strengths to improve the quality of life.

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce a partnership with HempStreet, India's first research to retail venture in the medicinal cannabis sector.

 

Headquartered in the UK, MGC Pharma has been working on polyherbal formulations based on cannabis and other phytopharmaceuticals. MGC Pharma has two proprietary formulations CimetrA™ and CannEpil©. CimetrA is effective in arresting the cytokine storm, a symptom of COVID-19. It is made of natural-sourced ingredients including Artemisinin, Curcumin, and Boswellia serrata. CannEpil© is a phytocannabinoid-based medicine that effectively treats drug-resistant Epilepsy. Both products have undergone successful Phase II clinical trials. Through this partnership, and through HempStreet's extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA™, which had an immediate need as there are currently over 15 million individuals (approximately 30% of all Covid-19 recoverees in India) said to be experiencing some form of post- or long- Covid- 19 related symptoms.

 

The partnership will also accelerate HempStreet's upcoming venture - transdermal delivery technology for cannabinoids - to launch in the markets beyond Asia with the help of MGC Pharma's widespread distribution network in Australia, the UK, Brazil, and Ireland.

Commenting on the partnership, Abhishek Mohan, Co-founder of HempStreet, said: "We are very excited to work with Roby and the team at MGC Pharma, bringing cutting-edge, scientifically-validated phytopharmaceutical medicines to tackle mass ailments in India and beyond. In particular, CimetrA™, which has shown a 100% success rate in Phase II clinical trials in India, will be an important product just on account of the fact that an estimated 15 million individuals are experiencing some sort of Post Covid-19 / Long Covid symptoms.

 

Further, Roby Zomer, Co-founder, MGC Pharma, said: "Entry into significant global markets such as India is paramount to MGC Pharma's agenda, advancing phytomedicine adoption globally. India has a long-established and government-supported Ayurvedic healthcare system, and working with HempStreet to facilitate access to our proprietary phytomedicines such as CimetrA and CannEpil© and the new formulations on the pipeline, is crucial to gaining a foothold in this market."

 

MGC Pharma is leaving its mark in the global medical cannabis industry by developing and supplying top-quality phytocannabinoid medicines in Europe, North America, and Australasia. This partnership is a significant step for MGC Pharma to tap into the Asian market while helping HempStreet expand its global footprint.

 

Together with MGC Pharma, HempStreet is committed to bring well-researched, highly efficient, and responsibly-dispensed phytomedicines to tackle mass ailments faced by people worldwide. With this partnership, HempStreet aims to combine the R&D and distribution strengths of both companies to improve the quality of life for hundreds of millions of people.

 

 

--Ends--

Authorised for release by the Board, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

 About HempStreet

 

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. The Company ensures end-to-end blockchain technology-based supply chain tracking to minimise any chance of abuse. HempStreet's dispensation network of more than 9,500 registered medical practitioners across 24 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. The company recently became India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADZGGKKDGGZZG
Date   Source Headline
30th Jun 20239:30 amRNSCompany Update
29th Jun 202310:22 amRNSResults of Shareholder’s General Meeting
1st Jun 20237:30 amRNSAppointment of Non-Executive Director
31st May 20237:00 amRNSFirst CannEpil® delivered to UK patients
30th May 20237:01 amRNSCorporate Update - Board and UK Adviser Changes
30th May 20237:00 amRNSDispatch of General Meeting Documents
18th May 202312:00 pmRNSDirector/PDMR Shareholding
10th May 20235:05 pmRNSDirector/PDMR Shareholding
2nd May 20237:00 amRNSMalta Production Facility Receives EU-GMP Approval
28th Apr 20237:13 amRNSMarch 2023 Quarterly Activities and Cash Flow
13th Apr 20237:00 amRNSFundraise closed raising a total of £2,090,890
11th Apr 20237:01 amRNS£1.2 million raised in a conditional Placing
11th Apr 20237:00 amRNSCannEpil® available by Named Patient Request in UK
3rd Apr 20237:00 amRNSApproval to Develop and Research with Psilocybin
21st Mar 20239:05 amRNSSecond Price Monitoring Extn
21st Mar 20239:00 amRNSPrice Monitoring Extension
21st Mar 20237:00 amRNSArtemiC Listed as OTC Drug; AMC Places US$2m order
15th Mar 20234:35 pmRNSPrice Monitoring Extension
15th Mar 20237:00 amRNSFirst patient enrolled in MGC ZAM App
8th Mar 20239:00 amRNSUS$500,000 funding received under Mercer Facility
7th Mar 20237:00 amRNSCompletion of CimetrA™ Mechanism of Action study
1st Mar 20237:02 amRNSAppointment of UK Lead Broker and Change of Co Sec
28th Feb 20239:08 amRNSHalf-year Report
10th Feb 20238:45 amRNSUpdated Investor Presentation
3rd Feb 20237:00 amRNSProvision of US$600,000 funding and change of CFO
2nd Feb 20237:00 amRNSExtension of Convertible Securities Agreements
30th Jan 20237:00 amRNSDecember 2022 Quarterly Activities and Cash Flow
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSChange of Adviser – SW4 Partners
11th Jan 20239:01 amRNSChange in External Financial Auditor
10th Jan 20237:00 amRNSCompletion of CimetrA™ Pre-clinical Trial
3rd Jan 20237:00 amRNSInternal Costs Review Completed and Board Change
28th Dec 20229:10 amRNSA$800,000 funding received under Mercer Facility
8th Dec 20221:47 pmEQSMGC Pharmaceuticals delivers its largest-ever order
7th Dec 20227:00 amRNSCompletion of CimetrA Efficacy Pre-clinical Trial
5th Dec 20227:00 amRNSDelivery of US$1m order of ArtemiC to AMC Holdings
2nd Dec 20227:00 amRNSPublication of MGC Pharma Glioblastoma research
28th Nov 20227:00 amRNSResult of AGM and Investor Presentation
22nd Nov 20227:00 amRNSWebsite Update
16th Nov 20229:00 amRNSNotice of AGM
9th Nov 202210:20 amRNSApplication for Admission to Trading
31st Oct 20227:00 amRNSSeptember Quarterly Activities and Cash Flow
25th Oct 20227:00 amRNSArtemiC Support - Long COVID Clinical Study Resuls
20th Oct 20227:00 amRNSOperations Update – Major Milestones Achieved
18th Oct 20229:00 amRNS2022 AGM Notice of Meeting and Annual Report
5th Oct 20221:03 pmRNSResults of Shareholder’s General Meeting
4th Oct 20227:00 amRNSAppointment of UK Advisor and Company Update
3rd Oct 20227:00 amRNSAnnual Financial Report
28th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.